Ryan N. Ptashkin

Director of New Technology @C2iGenomics 🧬 💻

[Ryan N. Ptashkin @RPtash]

@Elsa2Bernard @GustaveRoussy Congratulations!

[Nature Communications @NatureComms]

Recently published #CancerResearch: @ahmetz @RPtash @MEArcila @MSKPathology develop and test the #mskimpact Heme sequencing panel and platform to profile #BloodCancers in the clinic
@NatResCancer
https://t.co/VbnrUL2f4a

[Ahmet Zehir @ahmetz]

By now, i’m sure most of you saw that FDA is planning to regulate LDTs (https://t.co/94Jlrse9KF). A paper, suggesting clinical labs failed PT testing, is cited in the FDA doc as one of the reasons. What if the analyses in this paper were flawed? 🧵👇🏼 https://t.co/qscLEc5nd1

[Ryan N. Ptashkin @RPtash]

@KamalMe @MFBerger1 @WHOSTP Congratulations!

[Paz Polak @PolakPaz]

Thrilled to be attending #AACR2023 in Orlando! 😃 We're proud to present 3 posters and share how @C2iGenomics technology is making a real difference in MRD testing for cancer patients. I'd love to meet you over coffee at booth 1161 and chat more about it! ☕️ #MRD #WGS

[Ryan N. Ptashkin @RPtash]

@CDebyaniPhD @MFBerger1 @MSKCancerCenter @MSKPathology Congrats @MFBerger1 !

[Dan Landau @landau_lab]

🔥Extra-hot pre-print before this hellsite goes up in smoke 🔥

New horizons open up when sequencing costs go ↘️ @UltimaGenomics

Interested in deep cfDNA WGS for ultra-sensitive cancer detection? Duplex sequencing at genome scale?

https://t.co/DJeCo86ok8
Check out 🪡👇

[Ryan N. Ptashkin @RPtash]

@medrxivpreprint @MSKCancerCenter @ahmetz @MFBerger1 @RymaBenayed @ARoseBrannon @CDebyaniPhD With continued testing and data sharing, it is our belief that broad genomic assessment will support identifying novel drug targets for and improving noninvasive monitoring for response in all patients with hematologic cancers (7/n)

[Ryan N. Ptashkin @RPtash]

Happy to share our @medrxivpreprint on MSK-IMPACT Heme: a prospective clinical sequencing effort @MSKCancerCenter to guide the diagnosis, prognosis, & therapy selection for patients across hematologic malignancies 🧵(1/n) https://t.co/HckGIQq8yl

[Ryan N. Ptashkin @RPtash]

@medrxivpreprint @MSKCancerCenter @ahmetz @MFBerger1 @RymaBenayed @ARoseBrannon @CDebyaniPhD By removing rare germline variants from reporting through genotyping of candidate variants in matched normal tissue(s), we can better identify appropriate markers for MRD assessment and prevent false positive calls (6/n)

[Elizabeth McKenna @ElizSMcKenna]

This month's cover of @CD_AACR features work on mosaic variants in cancer susceptibility genes by @FresiaPareja @RPtash David Brown, Jorge Reis-Filho, Diana Mandelker and colleagues @MSKPathology @sloan_kettering https://t.co/WUUJFetTbw

[Elizabeth McKenna @ElizSMcKenna]

Now online in @CD_AACR: Cancer Causative Mutations Occurring in Early #Embryogenesis by @FresiaPareja @RPtash David Brown, Jorge Reis-Filho, Diana Mandelker and colleagues @MSKPathology @sloan_kettering https://t.co/WUUJFetTbw

[Ahmet Zehir @ahmetz]

It's Friday and it's time for a new preprint https://t.co/SEPcLItBYh : MSI status for cancer pts is critical as it is the first tissue-agnostic biomarker for treatment with pembrolizumab. We've been using NGS data from #MSKimpact + MSISensor to detect MSI status but 🧵 (1/n)

[David Steensma, MD @DavidSteensma]

The head of the United States Food and Drug Administration (!) @SteveFDA does not understand the difference between relative and absolute risk reduction -- a basic, fundamental concept in medicine, statistics and clinical trial interpretation. It just gets worse and worse.😢

[Ryan N. Ptashkin @RPtash]

@realDonaldTrump @SteveFDA “Must focus on speed, and saving lives” yet you promote hydroxychloroquine and conspiracy theories instead of science and leadership. More disturbing is your focus on re-election rather than American lives.

[Ryan N. Ptashkin @RPtash]

@BrunaLab @SadieRyan Enjoy :-)https://t.co/vWHxkA6KGb #rstats